ImmunityBio Inc (IBRX) Quote

IBRX in the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Anktiva is the next-generation immunotherapy drug, according to ImmunityBio executive chairman Dr. Patrick Soon-Shiong: "This drug is the first drug, as far as I know, that activates the natural killer cell that talks to the T-cell and generates complete remission..." pic.twitter.com/DIVc3A8luy— Yahoo Finance (@YahooFinance) April 23, 2024

Welcome

FDA approval!

https://www.investorsobserver.com/news/qm-news/8088196297645818

The FDA has accepted the BLA resubmission and will now review the therapy. It has set a Prescription Drug User Fee Act (PDUFA) date of 23 April 2024.

IBRX chart

Just curious, having read this article from June 2022, what makes us think that they will get approval for Antikva.

My concern just stems from the bottom of the article stating.

"Other drugs are in late-stage trials in combination with BCG for the same patient population, including AstraZeneca’s Imfinzi (durvalumab) and Sesen Bio’s Vicinium (oportuzumab monatox). The FDA previously rejected Sesen Bio’s BLA for the treatment of BCG-unresponsive patients, citing multiple issues, including a lack of randomised data comparing Vicinium with an investigator’s choice of intravesical chemotherapy."
https://www.pharmaceutical-technology.com/analyst-comment/immunitybio-first-marketed-drug/?cf-view

There is no comparator in the Antikva trial with any intravesical chemotherapy either, or against anything for that matter. As it's open-label single arm trial, with only Antikva being used. Will this be enough for FDA approval?

I know the prior CRL didn't mention anything about this, but that doesn't mean it isn't a potential issue?

Looking to be convinced wrong on the above :)

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Research tool: https://tradingtimeline.com/ibrx.html

https://www.oberlandcapital.com/news-post/immunitybio-announces-320-million-investment-by-oberland-capital/

https://www.otcmarkets.com/stock/IBRX

This stock is ready to breakout, did awesome today!!

https://www.otcmarkets.com/stock/IBRX

#IBRX 🔥 this stock can go crazy with 30% short interest! $IBRX

#IBRX 🔥 30% short interest and gap fill possibilities for big move! $IBRX

yup, i see that but….

….

i didnt like how each time it runs, they yank it right back down, so i moved on but im happy it ran for you some. just be careful, they dont seem to last long.

Just warming up…

News > Up 29%today > The FDA accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete.

then the usual dump, lol.

nice move so far today

$IBRX looks interesting

hopped in on this dip. i like the run it had last time.

IBRX under $2

https://www.otcmarkets.com/stock/IBRX

https://otcbb.swingtradebot.com/equities/IBRX

IBRX
ImmunityBio Inc
2.72
0.09 (3.42%)
Volume: 1,135,051
Day Range: 2.60 - 2.75
Last Trade Time: 7:59:29 PM EDT

IBRX
ImmunityBio Inc
2.69
-0.12 (-4.27%)
Volume: 6,333,343
Day Range: 2.63 - 2.85
Last Trade Time: 7:51:23 PM EDT

IBRX
ImmunityBio Inc
2.57
0.19 (7.98%)
Volume: 2,354,869
Day Range: 2.35 - 2.57
Last Trade Time: 7:56:03 PM EDT

IBRX an offering done right. bonzzzaaaa

#IBRX ?? gap fill after 3.3? Trade opportunity? $IBRX

-55% $IBRX received FDA CRL

Recall position was a catalyst play and not an investment which I clearly outlined in my thread.

Multiple times I tweeted that I closed my full position as stock appreciated a lot from entry point (Below $2) to almost 6+

Risk management is important for…— Pharmdca (@Pharmdca) May 11, 2023

The shorts are actually in IBRX and for a reason:

Total Cash (mrq) 107.18M
Total Cash Per Share (mrq) 0.25
Total Debt (mrq) 725.19M

https://www.nasdaq.com/market-activity/stocks/ibrx/short-interest

https://www.nasdaq.com/market-activity/stocks/ibrx/financials

Ouch! Sorry to anyone holding.

FDA denied

#IBRX ?? Will it pullback soon? Price action analysis $IBRX

#IBRX ?? time to cool? FDA approval soon?can it squeeze more? $IBRX

$IBRX This company is a game changer, and for investors, potentially a life changer. IMHO, this is true:

* Unrivaled vision targeting indications worth hundreds of billions.
* Multiple platforms synchronized to provide symbiotic pathways and a multi-faceted approach to both treatment and cures.
* People, patents, mfg plants on a scale typically seen only with big pharma
* Vision, scope, and claims backed up by stellar trial results that exceed SOC (including Keytruda).
* Potential for SOC, first line treatment, and preventative care ranging from cancer to covid (icing on an already huge cake)
* A billionaire backer with a proven track record who is unlikely to quit or sell.


https://ir.immunitybio.com/company/events-and-presentations
https://vimeo.com/808832939
https://vimeo.com/734512725
https://vimeo.com/822789555

#IBRX ?? watch this week for big move! Proce targets! $IBRX

IBRX
ImmunityBio Inc
2.82
0.20 (7.63%)
Volume: 4,004,591
Day Range: 2.48 - 2.895
Last Trade Time: 7:54:45 PM EDT

That day is getting closer.
Hang tight.

IBRX
ImmunityBio Inc
2.00
0.05 (2.56%)
Volume: 4,554,470
Day Range: 1.85 - 2.05
Last Trade Time: 7:59:22 PM EDT

Coyote Ugly



Watching for reversal

IBRX
ImmunityBio Inc
2.56
-0.18 (-6.57%)
Volume: 3,594,222
Day Range: 2.53 - 2.72
Last Trade Time: 5:05:22 PM EST

Approaching half a billion shares outstanding.
Even with such a good pipeline as soon as they get approval the stock will collapse.
Just like acer did.
It will get a small pump in May but everyone is waiting to sell apond approval.
Very heavily shorted tho.
80% held tight so a massive short squeeze could also take place .
But i would rule that out because the float is way too high.
Its a big gamble in or out .
No approval its game over.

Approaching half a billion shares outstanding.
Even with such a good pipeline as soon as they get approval the stock will collapse.
Just like acer did.
It will get a small pump in May but everyone is waiting to sell apond approval.
Very heavily shorted tho.
80% held tight so a massive short squeeze could also take place .
But i would rule that out because the float is way too high.
Its a big gamble in or out .
No approval its game over.

14,072,615 Shares of Common Stock

Warrants to Purchase up to 14,072,615 Shares of Common Stock

and

the Shares of Common Stock underlying the Warrants

We are offering 14,072,615 shares of our common stock, par value $0.0001 per share (the “common stock”), and warrants to purchase up to 14,072,615 shares of our common stock (and the shares of common stock issuable from time to time upon exercise of those warrants). Each share of common stock sold in this offering will be accompanied by a warrant to purchase one share of our common stock at an exercise price of $4.2636 per share. Each share of common stock and the accompanying warrant is being sold at a combined offering price of $3.5530. Subject to certain ownership limitations, the warrants will be immediately exercisable, and the warrants will expire two years after the initial issuance date. The shares of common stock and the warrants will be issued separately. We refer to the shares of common stock and the accompanying warrants, including the underlying shares of common stock, to be issued in this offering, collectively, as the “securities.”

2022 Top Story in Bladder Cancer: Use of N-803 With BCG in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer


The final results from an open-label multicenter study (NCT03022825) examining the use of N-803 with BCG in patients with BCG-unresponsive non–muscle invasive bladder cancer were presented at ASCO in June and published in the Journal of Clinical Oncology.1

N-803, an IL-15 super agonist that activates natural killer cells and CD8+ T cells, was combined with BCG and tested in patients in two cohorts: group A (carcinoma in situ [CIS]) and group B (papillary disease).

A total of 160 patients (83 with CIS and 77 with papillary disease) were enrolled, and the median number of prior BCG doses was 12. Patients received intravesical N-803 with BCG using standard induction and maintenance dosing.

The authors reported results for each cohort. Among patients with CIS, 71% (59/83) had a complete response, with a median duration of 24 months in responders. There was a 96% 2-year bladder cancer–specific progression-free survival in muscle-invasive bladder cancer. For patients with papillary disease, 12-month and 24-month disease-free survival rates of 57% and 48% were noted. At 2 years of follow-up, a total of 90% had avoided cystectomy.

Treatment was well-tolerated. Low-grade treatment-related adverse events were reported, including dysuria (22%) and urgency (12%), and there were no grade 4 or 5 adverse events. No immune-related serious adverse events occurred.

In summary, for patients with BCG-unresponsive disease, N-803 plus BCG offers a safe, effective, and well-tolerated treatment option.

This study is significant because treating BCG-unresponsive disease is challenging and patients have limited options. Also, many patients may not be eligible for or wish to undergo cystectomy. This important study offers a new option that can provide a durable treatment alternative for patients with a life-threatening bladder cancer diagnosis.

IBRX
ImmunityBio Inc
2.94
-0.14 (-4.55%)
Volume: 4,680,726
Day Range: 2.79 - 3.11
Last Trade Time: 5:35:01 PM EST

NK
NantKwest Inc
32.49
0.00 (0.00%)
Volume:

ImmunityBio, Inc. (IBRX)